Publication NumberUS 20190381116
Assignees
  • The Regents of the University of Michigan
Filing StatusPatent Application
US PAIR StatusDocketed New Case - Ready for Examination
US PAIR Status Date2019-11-27
Application Number16/085090
AvailabilityUnknown
Filing Date2017-03-15
Publication Date2019-12-19

Abstract

Provided herein are compositions and methods for administering bacterial strains to reduce GvHD and improve survival after allogeneic BMT.

Claims

  • 1. 1-3. (canceled)
  • 4. A method of treating Graft versus Host Disease (GvHD), the method comprising administering to a subject in need thereof a therapeutically effective amount of a bacterial composition, the bacterial composition comprising at least two bacterial strains comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO:17.
  • 5. The method of claim 4, wherein the bacterial strain comprises 16S rDNA sequences of at least 96%, at least 97%, at least 98%, or at least 99% homology.
  • 6. The method of claim 4, wherein the bacterial composition comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 bacterial strains.
  • 7. The method of claim 4, wherein the bacterial composition comprises bacterial strains comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.
  • 8. The method of claim 7, wherein the bacterial strain comprises 16S rDNA sequences of at least 96%, at least 97%, at least 98%, or at least 99% homology.
  • 17. The method of claim 4, wherein the bacterial strain does not have an antibiotic resistance gene.
  • 18. The method of claim 4, wherein the antibiotic resistance gene renders the bacterial strain resistant to vancomycin.
  • 19. The method of claim 4, wherein the bacterial strain produces butyrate.
  • 20. The method of claim 4, wherein the method does not include the administration of an antibiotic.
  • 21. The method of claim 4, wherein the bacterial composition is administered prior to bone marrow transplant.
  • 22. The method of claim 4, wherein the bacterial composition is administered after bone marrow transplant.
  • 23. The method of claim 4, wherein the bacterial composition is administered prior to and after bone marrow transplant.
  • 24. The method of claim 4, wherein the subject has chronic GvHD.
  • 25. The method of claim 4, wherein the subject has acute GvHD.
  • 35. The method of claim 4, wherein the bacterial composition is a pharmaceutical composition.
  • 36. The method of claim 4, wherein the pharmaceutical composition comprises a pharmaceutical acceptable excipient.
  • 37. The method of claim 4, wherein the pharmaceutical composition is formulated for oral administration.
  • 38. (canceled)
  • 39. The method of claim 4, wherein the pharmaceutical composition is formulated for delivery to the intestine.
  • 40. The method of claim 4, wherein the pharmaceutical composition is formulated for delivery to the colon.
  • 41. The method of claim 4, wherein one or more of the bacterial strains is lyophilized.
  • 42. The method of claim 4, wherein the pharmaceutical composition is in the form of a capsule.
  • 43. The method of claim 4, wherein the pharmaceutical composition further comprises a pH sensitive composition comprising one or more enteric polymers.
  • 27. 44-47. (canceled)

Also Published As

Related Grants

19 related grants.

Sign in to view

Related Publications

50 related publications.

Sign in to view

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.